# A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

> **NCT00642018** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 154 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** LY2181308 sodium
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00642018
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-08
- **Final completion:** 2012-04
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642018, "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00642018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*